On 18 September 2026, India got a headline it has waited two decades for: the country's first approved dengue vaccine has a distribution partner, a launch window, and a price tag nobody has announced yet. The fine print matters more than the headline.
Dr. Reddy's Laboratories and Japan's Takeda signed an exclusive agreement for QDENGA in India's private market. The vaccine already cleared India's regulator — the Central Drugs Standard Control Organization approved it in July 2026 for people aged 4 to 60. But availability is expected only in the first half of 2027.
Read that gap again. Approval: done. Partner: signed. Doses in your paediatrician's fridge: not before 2027, and the announced window runs all the way to June. Which means this dengue season, and very likely the next one, you are on your own with the same old tools — a mosquito net, a clean water tank, and the thing most Indian families still get wrong when the fever actually arrives.
What exactly was announced
Under the agreement, Dr. Reddy's will promote and distribute QDENGA across India's private market for both paediatric and adult vaccination. Takeda keeps the public-market rights, manufacturing, importation and overall medical and brand oversight. As the company's own stock-exchange disclosure notes, there was no upfront payment or milestone payment involved — the rest of the commercial terms stay confidential.
The basics of the vaccine itself, per the companies' announcement:
- What it is: QDENGA (TAK-003), a live-attenuated tetravalent vaccine built on a DENV-2 backbone carrying structural proteins from DENV-1, DENV-3 and DENV-4 — so it covers all four serotypes.
- Schedule: two doses, three months apart. Both are needed.
- Approved age band in India: 4 to 60 years.
- No pre-test needed: unlike the older Dengvaxia, it does not require a blood test proving you had dengue before. The WHO has prequalified the vaccine, and its position paper on dengue vaccines recommends it without pre-vaccination screening in highly endemic countries.
- Track record: approved in 43 countries since 2022, with over 32 million doses distributed, including Brazil's national immunisation programme.
Takeda's India head also flagged something worth watching: the Parliamentary Committee on Health recommended that a dengue vaccine be considered for India's Universal Immunization Programme. That is a recommendation, not a decision — but it is the first serious signal that this may not stay a private-market product forever.
How well does it actually work? The honest numbers
This is where most coverage stops at "vaccine approved" and moves on. The trial data deserves a closer look, because it decides who should be first in line.
QDENGA's pivotal Phase 3 trial — TIDES, Takeda's largest study ever — enrolled 20,071 children and adolescents aged 4 to 16 across eight dengue-endemic countries in Asia and Latin America. The results published in The Lancet Global Health show that at 4.5 years:
- 61.2% efficacy against virologically confirmed dengue (95% CI 56.0–65.8)
- 84.1% efficacy against dengue hospitalisation (95% CI 77.8–88.6)
- In people who had never had dengue before, those figures were lower: 53.5% and 79.3% respectively
Takeda completed the full seven-year follow-up in November 2025. An exploratory booster dose at 4.5 years took efficacy to 74.3% against confirmed dengue and 90.6% against hospitalisation — an increase Takeda itself describes as marginal — with no new safety signals reported.
So: roughly six in ten symptomatic infections prevented, but more than eight in ten hospitalisations prevented. That second number is the real story. Severe dengue is driven mainly by plasma leakage and shock, not by the fever itself. A vaccine that cuts the chance of catching it by about 60% but cuts the chance of hospital admission by 84% is doing exactly the job that matters.
One thing to hold on to while reading those percentages: they come from a trial in children and adolescents aged 4 to 16. That is who was measured.
The caveats nobody is putting in the press release
Three of them, and all three are worth knowing before you book a slot in 2027.
One: the WHO's recommendation is narrower than India's approval. India cleared the vaccine for ages 4 to 60. The World Health Organization recommends programmatic use only in children aged 6 to 16 living in areas with high dengue transmission intensity, and explicitly does not recommend routine use below age 6 because efficacy is lower in that group.
Two: there is an unresolved question about serotypes 3 and 4. The same WHO guidance states that until the efficacy-risk profile for DENV-3 and DENV-4 in dengue-naive (seronegative) people is better assessed, it does not recommend programmatic use in low-to-moderate transmission settings. This matters for India specifically. A pan-India molecular surveillance study published in the International Journal of Infectious Diseases tested 6,889 dengue-positive samples referred to 45 Viral Research and Diagnostic Laboratories. Every region showed co-circulation of multiple serotypes, eight states had all four circulating together, and DENV-2 was predominant. The study also found that concurrent infection with multiple serotypes was directly associated with a higher likelihood of thrombocytopenia, arthralgia and haemorrhagic manifestations than single-serotype infection. Dr. Reddy's and Takeda, citing that study, put the concurrent-infection rate at about 1 in 14 patients.
Three: it is a live vaccine, so it is not for everyone. Per the approved product information, QDENGA is contraindicated in pregnancy and breastfeeding, and in people who are immunocompromised. Women of childbearing potential are advised to avoid pregnancy for at least one month after vaccination. There is also no efficacy trial data in anyone over 16 — protection in adults is inferred from immune response, not measured directly against infection.
None of this makes the vaccine a bad idea. It makes it a medical decision for your doctor, not a Sunday WhatsApp forward.
Meanwhile, the 2026 season is not waiting
The scale is easy to underestimate. India's own National Center for Vector Borne Diseases Control recorded 289,235 dengue cases and 485 deaths in 2023, and 233,519 cases and 297 deaths in 2024 — figures also cited in peer-reviewed research on India's dengue control strategy. And the disease no longer behaves like a monsoon guest — transmission now runs year-round across much of the country.
Delhi is the clearest live example. Municipal Corporation of Delhi data showed the capital at 432 dengue cases in 2026, of which 121 came in September alone up to the 12th — making September the heaviest month of the year so far. West Delhi led the count, followed by Central Delhi and Shahdara North. The same period logged 183 malaria and 24 chikungunya cases.
India is also building its own. DengiAll, the indigenous candidate, entered Phase 3 in a trial run by ICMR with Panacea Biotec — over 10,335 healthy adults across 19 sites in 18 states, with a two-year follow-up period. Those results are still awaited.
Add it up: an imported vaccine arriving in private clinics sometime in the first half of 2027, a domestic one still in follow-up, and a season happening right now. The next 12 to 18 months are governed entirely by prevention and by what you do in the first 72 hours of a fever.
The part Indian households get wrong: fluids
There is still no antiviral for dengue. Treatment is supportive, and the single biggest lever available to a family at home is fluid management. Here the instinct — "bas paani piyo, khoob paani piyo" — is not quite right.
Home-care guidance presented in WHO South-East Asia Region's dengue case-management series is specific on this point: plain water alone can cause electrolyte imbalance, particularly low serum sodium, and oral electrolyte solution is recommended instead. The reasoning is that dengue drains fluid through fever, sweating, poor appetite and vomiting, and what leaves the body is not just water — sodium goes with it. On that guidance, replacing the volume with plain water alone can worsen the sodium imbalance rather than fix it.
The trial evidence points the same way, and it is worth being honest about how strong it is. A randomised trial comparing an oral isotonic solution against plain water in dengue patients found the isotonic group had less nausea and vomiting, a positive fluid balance and higher mean arterial pressure, and became fever-free faster — though the differences did not reach statistical significance, so the authors describe it as a trend rather than proof.
What is statistically solid is the volume. A prospective primary-care study found patients who drank at least five glasses of fluid in the previous 24 hours had significantly fewer clinical warning signs at their first consultation (p = 0.044). That same study found no association between the type of fluid and warning signs — so the drinking-enough part is the proven bit, and the electrolyte part rests on WHO's guidance about sodium rather than on that trial.
Practical rules, straight from clinical guidance:
- ORS first, alongside soft foods, fruit juice and milk — PAHO's patient guidance says fluids, "preferably oral rehydration salts", and not to self-medicate.
- Drink generously. CDC's 2026 Yellow Book tells clinicians to encourage abundant oral hydration in every patient able to drink, ambulatory or hospitalised.
- Track urine output. No urine for 4 to 6 hours is on the list of signs that mean hospital, not wait-and-see.
- No aspirin, no NSAIDs, no steroids. The stated risks are severe bleeding, acute hepatitis and acute kidney injury. Paracetamol only, at the doses your doctor sets.
- Avoid black or red-coloured foods and drinks. They make it harder to tell whether a patient is vomiting blood.
- Beware of the drop in fever. PAHO is blunt about this: patients who worsen as the fever comes down are the warning-sign cases. Warning signs generally begin in the 24 to 48 hours after the fever has gone.
Warning signs that mean hospital, now
Do not wait for a platelet number. Go immediately if you see severe abdominal pain or tenderness, persistent vomiting, bleeding from gums or nose, blood in vomit or stool, lethargy or restlessness, cold clammy skin, breathlessness, or a sudden inability to keep fluids down.
What this means for everyday hydration
One thing the dengue guidance settles is a wider point about ordinary hydration: the body loses minerals along with water, so in heat or heavy sweating, replacing only the water is an incomplete fix. That holds in a Delhi summer, on a gym floor, or after a long day on the road — and it is why we built Amaayu Electrolyte Water around sodium, potassium and magnesium rather than flavour alone.
The limit matters more than the pitch, so plainly: an electrolyte water is not an oral rehydration solution, and no functional water treats dengue. ORS is formulated to a specific glucose-and-sodium ratio meant to treat fluid loss in illness; an everyday electrolyte drink is built for ordinary sweat loss, which is a different job and a different formulation. If someone at home has a suspected dengue fever, what belongs in your hand is an ORS sachet from the chemist and a doctor on the phone — not a wellness beverage, ours included.
The bottom line
India's first dengue vaccine is real, approved, and coming through Dr. Reddy's private network in the first half of 2027 for ages 4 to 60. It cut dengue hospitalisations by roughly 84% over 4.5 years in children aged 4 to 16 in the trial, it needs two doses three months apart, and it is not suitable for pregnant, breastfeeding or immunocompromised people. Talk to your doctor when it lands — especially if there is a child in the 6 to 16 band in a high-transmission city.
Until then, nothing has changed about what protects your family: no standing water around the house, mosquito protection through the day since Aedes bites in daylight, and the discipline to treat a fever with ORS and a doctor's eyes on it, rather than a jug of plain water and hope.
Frequently asked questions
When will the dengue vaccine be available in India?
QDENGA is expected to become available in India's private market in the first half of 2027, subject to completion of processes with local authorities. It received CDSCO marketing authorisation in July 2026.
What is the price of the dengue vaccine in India?
No price has been announced. Dr. Reddy's and Takeda have not disclosed the commercial terms of their agreement, and pricing is typically confirmed closer to launch.
Who can take QDENGA?
It is approved in India for individuals aged 4 to 60 years, given as two doses three months apart. It is contraindicated in pregnancy and breastfeeding, and in immunocompromised individuals. A doctor's assessment is required.
Do I need a blood test before the dengue vaccine?
No. Unlike the earlier Dengvaxia, QDENGA does not require pre-vaccination screening for past dengue infection, and WHO has recommended it without pre-vaccination screening for use in highly endemic countries.
Is plain water enough during dengue fever?
No. WHO South-East Asia Region home-care guidance advises against relying on plain water because it can worsen electrolyte imbalance, especially low sodium. Oral rehydration solution is recommended, under medical supervision.
This article is for general information and awareness. It is not medical advice, and Amaayu products are not intended to diagnose, treat, cure or prevent any disease. Dengue requires assessment and treatment by a registered medical practitioner.